(NASDAQ: NTLA) Intellia Therapeutics's forecast annual revenue growth rate of 44.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.76%.
Intellia Therapeutics's revenue in 2023 is $52,121,000.On average, 9 Wall Street analysts forecast NTLA's revenue for 2023 to be $5,036,562,505, with the lowest NTLA revenue forecast at $1,643,294,921, and the highest NTLA revenue forecast at $10,562,152,680. On average, 8 Wall Street analysts forecast NTLA's revenue for 2024 to be $5,054,870,237, with the lowest NTLA revenue forecast at $426,887,004, and the highest NTLA revenue forecast at $13,249,340,358.
In 2025, NTLA is forecast to generate $15,754,330,902 in revenue, with the lowest revenue forecast at $2,640,538,170 and the highest revenue forecast at $41,808,521,025.